January 20, 2026
Finance

Notable Gains in Select Biotech and Healthcare Stocks Amid Overall Market Decline

Corvus Pharmaceuticals and Other Leading Stocks Rally Despite Dow Jones Slide

Loading...
Loading quote...

Summary

U.S. stock markets saw a general downturn on Tuesday, with the Dow Jones Industrial Average declining by approximately 700 points. However, several notable companies, particularly in the pharmaceutical and healthcare sectors, experienced significant stock price gains driven by pivotal clinical trial updates, regulatory meetings, and strategic corporate announcements.

Key Points

Corvus Pharmaceuticals shares surged 90.3% following encouraging Phase 1 clinical trial results for soquelitinib in treating moderate to severe atopic dermatitis.
Rapt Therapeutics stock rose 63.8% after GSK announced plans to acquire the company.
Immunitybio advanced 24.3% on the announcement of an FDA End-of-Phase meeting for its bladder cancer treatment application.
Acadia Healthcare shares increased 21.2% subsequent to appointing Debbie Osteen as CEO and reaffirming fiscal 2025 guidance.

On Tuesday, the broader U.S. equity markets experienced a downturn as the Dow Jones Industrial Average dropped roughly 700 points. Despite this negative market environment, a subset of prominent stocks, particularly within the biotechnology and healthcare sectors, delivered substantial price appreciation.

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) emerged as the standout performer among these stocks, following the release of promising results from the fourth cohort in its randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating the drug soquelitinib. This trial targeted patients suffering from moderate to severe atopic dermatitis. The disclosure of encouraging trial outcomes contributed to a surge in Corvus Pharmaceuticals’ shares, which soared approximately 90.3%, closing at $15.32 during Tuesday's trading session.

Several other companies also posted considerable gains, propelled by positive clinical, regulatory, or corporate actions. Rapt Therapeutics Inc (NASDAQ:RAPT) saw its stock price increase by 63.8%, reaching $57.52 after GlaxoSmithKline (GSK) announced its intention to acquire the company.

Immunitybio Inc (NASDAQ:IBRX) advanced 24.3%, closing at $6.86. This uplift followed the company’s announcement of an FDA Type B End-of-Phase meeting for its supplemental Biologics License Application concerning ANKTIVA combined with Bacillus Calmette-Guérin. The application targets the treatment of BCG-unresponsive non-muscle invasive bladder cancer characterized by papillary tumors.

Acadia Healthcare Company Inc (NASDAQ:ACHC) reported a 21.2% rise in its stock price to $14.15. The increase was linked to the appointment of Debbie Osteen as the new CEO and the firm’s reaffirmation of its fiscal year 2025 guidance.

Additional significant movers included Titan Mining Corp (NYSE:TII), which gained 20.2% to $4.89, and United Microelectronics Corp (NYSE:UMC), which rose 15.8% to $10.78. Korea Electric Power Corp (NYSE:KEP) followed with a 15.7% increase, closing at $21.71.

Iamgold Corp (NYSE:IAG) experienced a 14.6% surge, ending the day at $19.69. The company disclosed preliminary operating results for 2025, projecting gold production of approximately 765,900 ounces. In addition, it issued guidance for 2026 with an anticipated range of 720,000 to 820,000 ounces.

Hycroft Mining Holding Corporation (NASDAQ:HYMC) increased 12.2% to $38.85, while SK Telecom Co Ltd (NYSE:SKM) moved upward by 10.2% to a share price of $23.12. USA Rare Earth Inc (NASDAQ:USAR) recorded a 10.1% gain, closing at $19.48, following plans to develop a 3,750 metric tons per annum metal and alloy production facility in Lacq, France.

Lumentum Holdings Inc (NASDAQ:LITE) and SanDisk Corp (NASDAQ:SNDK) closed with gains of 7.1% and 7% respectively, at $347.31 and $442.51. These increases contributed positively to their respective market performance despite prevailing market pressures.

This notable stock performance among specific biotech and healthcare firms, as well as select mining and technology companies, highlights the divergent market trends impacting sectors differently amid broad indices' declines.

Risks
  • Overall U.S. stock market exhibited significant declines, potentially influencing individual stock performance volatility.
  • Clinical trial results, while promising, are preliminary and could impact future developments if not corroborated by subsequent phases.
  • Regulatory approvals, such as FDA meetings, do not guarantee eventual licensing or market success.
  • Corporate changes (e.g., CEO appointment) and guidance reaffirmations may be subject to change based on future operational contexts.
Disclosure
Education only / not financial advice
Search Articles
Category
Finance

Financial News

Ticker Sentiment
CRVS - positive RAPT - positive IBRX - positive ACHC - positive TII - positive
Related Articles
Becton Dickinson Faces Market Headwinds Amid Transition and Revised Earnings Projections

Becton Dickinson & Co. posted first-quarter earnings above analyst expectations but trimmed its fisc...

AstraZeneca Posts Solid Q4 Earnings, Shares Rally Near 52-Week High

AstraZeneca Plc reported fourth-quarter 2025 revenue of $15.50 billion, slightly above expectations,...

Evommune Shares Surge Amid Positive Phase 2a Data for Atopic Dermatitis Treatment

Evommune, Inc. witnessed a sharp increase in its stock price following the release of encouraging to...

Nektar Therapeutics Shares Surge on Strong Atopic Dermatitis Trial Data

Nektar Therapeutics' stock experienced a significant gain following the release of positive 36-week ...

Phio Pharmaceuticals Reports Promising Tumor Clearance in Skin Cancer Trials, Shares Jump

Phio Pharmaceuticals Corp. announced encouraging Phase 1b data for its lead drug candidate PH-762 in...

Major U.S. Stocks Climb Following Strong Earnings Reports and Positive Guidance

U.S. equity markets moved higher on Tuesday, driven by Datadog's significant share price increase fo...